StockIQ.techRegeneron Pharmaceuticals Inc. (REGN) Stock Analysis
Free AI-powered analysis and research for Regeneron Pharmaceuticals Inc. stock
Sector: Healthcare
REGN snapshot
Data as of 3 Nov 2026 close. Updated daily.
Regeneron Pharmaceuticals Inc. scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 99% of its 52-week range, up 50.9% over the past year. Latest reported figures show a profit margin of 27.9%, return on equity of 14.0% and revenue growth of +16.7%.
What is driving the score
- RSI Very High (82): -5
- Strong Uptrend: +11
- MACD Bullish: +8
- Strong Revenue Growth (16.7%): +8
- Excellent Profit Margin (27.9%): +10
- Low Debt (0.09 D/E): +8
- Strong Liquidity (3.33 Current Ratio): +8
- Strong Long-term Uptrend: +8
- Strong Rise (+50.9% over 1 year): +10
- Near 52-Week High (99%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full REGN report
Regeneron Pharmaceuticals Inc. (REGN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze REGN Now →📰 Latest Update
Regeneron (REGN) Stock Looks At A Discount To Earnings
Sat, October 31, 2026 at 6:13 PM UTC 2 min read
Regeneron Pharmaceuticals' stock, currently priced at US$928.61, has seen significant gains, raising questions about whether its earnings justify the valuation. The company reports a P/E ratio of about 21.4x, which is below the biotech industry average, suggesting the shares may be undervalued. Recent strong revenue and earnings, driven by successful drugs like Dupixent and Eylea HD, support expectations for continued profit growth, although concerns about potential risks remain.